About: http://data.cimple.eu/news-article/1028bba5cc8c6b91a65e59b1c3618d6de6e19dff5dd01fc78a73382f     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Shares of US drugmaker Gilead Sciences rocketed higher Friday following a report recounting a promising performance for an antiviral medication being tested to treat the coronavirus. The report in Stat News described a video discussion in which the head of clinical trials at the University of Chicago Medical School said almost all of the patients in a research group had been discharged after being treated with Gilead's remdesivir. The group of 125 patients, most with severe COVID-19 symptoms, suffered just two fatalities, Stat reported. Gilead told the health news website that it would comment when more data is available. The California-based company's shares jumped 8.0 percent to $82.65 in late-morning trading after earlier surging as much as 12 percent. On April 10, Gilead commented only cautiously following a positive writeup of another remdesivir study in the New England Journal of Medicine. Researchers in the New England Journal study analyzed data from 53 patients, 25 of whom were discharged and seven of whom died. Limitations in the study included "the small size of the cohort, the relatively short duration of follow-up... and the lack of a randomized control group," the article said. Still, the data "suggest that remdesivir may have clinical benefit in patients with severe COVID-19," the article said. Following the New England Journal piece, Gilead Chief Executive Daniel O'Day said seven clinical trials have been launched on the drug and the company expects to have preliminary data for patients with severe symptoms by late April. "We are working with intense speed to determine whether remdesivir could be an option and we are committed to sharing information when it becomes available to us," O'Day said. jmb/cs
schema:headline
  • Gilead shares surge on promising COVID-19 drug report
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software